Atreca, Inc.

Equities

BCEL

US04965G1094

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 02:32:29 2024-04-25 pm EDT			5-day change	1st Jan Change
0.0855 ^USD	+0.59%		+12.35%	-35.23%

Apr. 17	North American Morning Briefing : Stock Futures -2-	DJ
Apr. 10	North American Morning Briefing : Traders Await -2-	DJ

Atreca, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022

August 08, 2022 at 04:05 pm EDT

Atreca, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported net loss was USD 27.88 million compared to USD 26.68 million a year ago. Basic loss per share from continuing operations was USD 0.72 compared to USD 0.72 a year ago.
For the six months, net loss was USD 52.75 million compared to USD 52.45 million a year ago. Basic loss per share from continuing operations was USD 1.38 compared to USD 1.42 a year ago.

Latest news about Atreca, Inc.

North American Morning Briefing : Stock Futures -2-	Apr. 17	DJ
North American Morning Briefing : Traders Await -2-	Apr. 10	DJ
Atreca, Inc.(OTCPK:BCEL) dropped from S&P TMI Index	Mar. 20	CI
Atreca, Inc.(OTCPK:BCEL) dropped from NASDAQ Composite Index	Mar. 17	CI
Atreca, Inc. Announces Board Resignations	Feb. 06	CI
Immunome Signs Asset Purchase Agreement for Acquisition of Antibody-Related Assets From Atreca	Dec. 26	MT
Immunome, Inc. entered into an agreement to acquire Substantially all Assets of Atreca, Inc. for $12.5 million.	Dec. 25	CI
Atreca, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Atreca, Inc. to Continue Exploring Strategic Alternatives	Nov. 13	CI
Investors Remain Cautious Over Fed Moves, Setting Wall Street Up for Lower Open	23-10-20	MT
Top Premarket Gainers	23-10-19	MT
Atreca to Terminate Lease on California Headquarters; Chief Financial Officer Resigns	23-09-21	MT
Atreca, Inc. Appoints Rick Ruiz as the Principal Accounting Officer	23-09-21	CI
Atreca, Inc. Announces Resignation of Herbert Cross, Chief Financial Officer	23-09-21	CI
AnaptysBio Names John Orwin as Board Chairman	23-09-18	MT
North American Morning Briefing : China Angst -2-	23-08-15	DJ
Wedbush Downgrades Atreca to Neutral From Outperform on Heels of Announced Discontinuation of Lead Asset ATRC-101, Lowers PT to $1 From $4	23-08-14	MT
North American Morning Briefing : Stock Futures -2-	23-08-14	DJ
Brookline Capital Downgrades Atreca to Hold From Buy	23-08-11	MT
Stifel Downgrades Atreca to Hold From Buy, Adjusts Price Target to $1 From $4	23-08-11	MT
HC Wainwright Downgrades Atreca to Neutral From Buy	23-08-11	MT
Atreca, Inc. Reduces its Workforce by Approximately 40%	23-08-10	CI
Atreca, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Atreca, Inc. Presents Data from Ongoing Phase 1b Study of ATRC-101 in Patients with Select Advanced Solid Tumors During Oral Abstract	23-06-05	CI
Stifel Adjusts Price Target on Atreca to $4 From $5, Maintains Buy Rating	23-05-11	MT

Chart Atreca, Inc.

Duration

Period

More charts

Company Profile

Atreca, Inc. is a clinical-stage biopharmaceutical company. The Company is discovering and developing antibody-based therapeutics to treat a range of solid tumor types. Its most advanced product candidate, ATRC-101, is a monoclonal antibody with a mechanism of action and target derived from an antibody identified using its discovery platform. ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. It commenced clinical development of ATRC-101 with a Phase Ib clinical trial evaluating ATRC-101 as a monotherapy in patients with select solid tumors and opens a new cohort to evaluate ATRC-101 in combination with pembrolizumab, a PD-1 checkpoint inhibitor. It is also advancing additional product candidates using its discovery platform. Its oncology programs include APN-497444, an ADC against a tumor glycan target, and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.0855 USD

Average target price

2 USD

Spread / Average Target

+2,239.18%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ATRECA, INC.	-35.23%	3.39M
VERTEX PHARMACEUTICALS INCORPORATED	-2.26%	103B
REGENERON PHARMACEUTICALS, INC.	+1.41%	95.71B
ARGENX SE	+0.79%	22.02B
BIONTECH SE	-17.84%	20.9B
GENMAB A/S	-11.11%	17.85B
WUXI APPTEC CO., LTD.	-42.83%	16.21B
BEIGENE, LTD.	-17.63%	15.52B
NEUROCRINE BIOSCIENCES, INC.	+4.55%	13.86B
SAREPTA THERAPEUTICS, INC.	+32.11%	12.04B

Bio Therapeutic Drugs